Physician profile
Romi Bhasin
NPI 1588653711
$5,056.12
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $542 · 2021: $898 · 2022: $727 · 2023: $847 · 2024: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $756.96 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $458.53 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $356.35 | 2021-2024 | |
| Lilly USA, LLC | $300.14 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $280.77 | 2019-2022 | |
| Amgen INC. | $270.36 | 2019-2024 | Prolia, Evenity, Tepezza |
| Abbvie INC. | $259.10 | 2019-2024 | Synthroid |
| Radius Health, INC. | $167.27 | 2019-2024 | Tymlos |
| Antares Pharma, INC. | $149.62 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.42 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $137.66 | 2019-2021 | |
| Ibsa Pharma INC. | $134.90 | 2019-2023 | Tirosint, Licart |
| Dexcom, INC. | $124.21 | 2019-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $107.71 | 2022-2024 | |
| Cequr Corporation | $105.79 | 2022-2024 | Cequr Simplicity |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romi Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.